Several weight-loss drugs, particularly GLP-1 receptor agonists like tirzepatide and semaglutide, were initially developed for diabetes but have since become widely used for obesity management. The US FDA and the European Medicines Agency have approved several weight-loss medications, including tirzepatide, semaglutide, liraglutide, orlistat, naltrexone/bupropion, and phentermine/topiramate.
Beyond aiding in weight loss and diabetes management, these drugs provide significant health benefits, such as reducing the risk of cardiovascular diseases, lowering the incidence and recurrence of alcohol use disorder, and improving kidney function. However, they are associated with adverse effects, including gastrointestinal issues (semaglutide, tirzepatide, and liraglutide), hypertension (naltrexone/bupropion), psychological side effects (topiramate, phentermine/topiramate), and sleep disorders…
